A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent ...

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma ...

While not FDA approved, rituximab combined with lenalidomide (Revlimid) has emerged as a potential chemotherapy-free first-line option for advanced follicular lymphoma.

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma Print details Share Facebook Twitter ...

How this study might affect research, practice or policy To adopt combination B cell targeting with rituximab and belimumab in clinical practice, we now present reassuring long-term clinical and ...

Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.

The study aims to evaluate the safety and efficacy of odronextamab compared to rituximab combined with chemotherapy in treating follicular lymphoma, a type of non-Hodgkin lymphoma.

MONDAY, June 23, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Late-onset neutropenia is emerging as a common adverse effect of rituximab when used in the treatment of autoimmune diseases. Is this late effect as widespread as it seems?

Genentech’s lymphoma portfolio is one of the broadest in the industry, providing a unique and much-needed opportunity to combine regimens with different and complementary mechanisms of action.